Bpifrance

Ecoat develops bio-based chemistries tailored for the coatings industry, focusing on sustainable solutions. The company offers a range of water-based, bio-based products, including bio-based alkyd emulsions, acrylics, and specialty oils. Its product lineup features innovative offerings such as secoia, inokem, air purifying emulsions, and solkem, all designed to promote environmental sustainability within the paint and coating sector. By emphasizing the adoption of eco-friendly materials, Ecoat aims to facilitate the industry's transition towards more sustainable practices.

MSInsight is a bioinformatics startup that specializes in developing diagnostic and treatment response prediction solutions for cancers with Microsatellite Instability (MSI). The company's core offering revolves around identifying and analyzing diagnostic and prognostic biomarkers of treatment response in MSI tumors. By leveraging next-generation sequencing data, MSInsight's platform provides actionable insights on MSI status, a critical biomarker for cancer treatment, enabling healthcare professionals to make informed decisions about patient care, particularly in relation to immunotherapy options, and ultimately improve patient outcomes.

GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, focused on developing gene therapy treatments for retinal degenerative diseases and neurodegenerative conditions affecting the central nervous system. Utilizing its core technology platforms—Mitochondrial Targeting Sequence and Optogenetics—the company aims to preserve and restore vision in patients with severe retinal disorders. Its lead product candidates include GS010, an AAV2-based gene therapy currently in Phase III trials for treating Leber hereditary optic neuropathy caused by mutations in the ND4 gene, and GS030, which is undergoing Phase I/II trials for retinitis pigmentosa and geographic atrophy in dry age-related macular degeneration. In addition to these, GenSight is advancing several products in preclinical stages targeting various ophthalmic and neurodegenerative diseases. Founded in 2012, the company is dedicated to innovative approaches that aim to prevent vision loss and improve the quality of life for affected patients.

Terratis, a French company, specializes in large-scale pest control using the Sterile Insect Technique (SIT). They focus on reducing populations of tiger mosquitoes and agricultural pests by releasing sterilized male insects, providing a chemical-free, environmentally sustainable solution for public health authorities and agricultural sectors.

Mabqi, headquartered in Grabels, France, is a biopharmaceutical company specializing in immunotherapy. It operates an antibody discovery platform, enabling the identification and development of innovative, proprietary therapeutic molecules.

EG 427 is a French biotechnology company that specializes in pinpoint gene therapy, aimed at treating disorders related to spinal cord injuries. The company utilizes HSV-1-based vectors, leveraging the natural characteristics of the Herpes Simplex Virus 1 to establish lifelong latency in peripheral neurons. This innovative approach allows for targeted and sustained expression of therapeutic genes, providing a potential cure for severe, chronic, and localized conditions, such as neurogenic bladder disorders resulting from spinal cord injuries. By focusing on this advanced gene therapy technique, EG 427 seeks to improve treatment outcomes for patients suffering from these debilitating conditions.

SUPERBRANCHE is a biotechnology company focused on the early detection and treatment of metastases using advanced nanotechnology. The company develops therapeutic and diagnostic applications that aim to enhance accessibility and facilitate the timely identification of tumors. Its innovative platform incorporates targeted diagnostic and image-guided therapy nanomaterials, grounded in proprietary technology. This approach enables healthcare providers to detect and address metastases earlier, ultimately improving patient outcomes.

Coave Therapeutics specializes in developing gene therapies aimed at treating rare ocular and central nervous system diseases. The company focuses on innovative solutions for rare retinal disorders, utilizing a recombinant adeno-associated virus that substitutes the viral DNA with a functional copy of the PDE6B gene. This therapeutic approach involves injecting the corrected version of the protein between the photoreceptors and the retinal pigment epithelium, providing patients with effective treatment options for various eye conditions.

NEBULA maps 3D macromolecule using dataset-free genAI and physics, enhancing drug target discovery, which forms the basis of all new drugs.

BiPER Therapeutics is a biotechnology company focused on developing and commercializing innovative therapeutics. The company specializes in creating drugs that target critical proteins involved in the metabolism of cancer cells, aiming to address treatment resistance and enhance cancer cell survival. Its therapeutic offerings are particularly aimed at the treatment of gastrointestinal cancers, providing potential solutions for patients facing these challenging conditions.

Biomemory is a deep-tech company focused on advanced data storage solutions for large enterprises and organizations. It specializes in molecular engineering to create innovative, bio-based data storage drives that utilize long DNA strands for data retention. This approach offers a cost-effective and energy-efficient alternative to traditional storage methods such as solid-state drives and magnetic tape. Biomemory's technology allows for the stable storage of vast amounts of data at ambient temperatures without requiring energy input or generating CO2 emissions. As a result, its storage media are designed to be durable for thousands of years, providing a sustainable solution for the growing demands of data centers.

Vetbiolix is a veterinary biotechnology company dedicated to developing innovative therapeutic solutions for dogs and cats. The company focuses on creating first-in-class drug candidates aimed at treating and preventing diseases that affect pets, particularly in areas such as periodontitis, osteoarthritis, and gut motility disorders. By emphasizing clinical development, Vetbiolix strives to offer effective treatments for common health issues in pets, ultimately enhancing their quality of life.

Orakl Oncology specializes in expediting cancer drug discovery by employing advanced biology and AI-driven analysis. It maintains a unique collection of patient tumor avatars, integrating biological and clinical data, to create realistic tumor models that mimic real-life drug responses. By mining multi-modal experimental data and combining it with deep patient data, Orakl enables oncology companies to identify relevant targets and develop more effective treatments at an accelerated pace.

Meiogenix is a biotechnology company focused on developing innovative breeding technologies aimed at unlocking the untapped genetic diversity of various organisms. By modulating the frequency of homologous recombination in eukaryotic cells, the company enhances natural biodiversity. This approach enables the creation of new products that can help tackle pressing global food and industrial challenges. Through its advancements, Meiogenix contributes to the exploration and application of genetic resources, ultimately aiming to improve agricultural and industrial outputs.

Afyren is a sustainable chemistry company focused on developing innovative biotechnological solutions that valorize non-food biomass while promoting environmental sustainability. The company aims to replace petroleum-based ingredients with bio-sourced products, aligning its operations with a circular and low-carbon economy. Utilizing natural microorganisms, Afyren produces a range of seven organic acids derived entirely from renewable sources, along with a high-value-added fertilizer. Through its efforts, Afyren contributes to the transformation of the chemical industry by providing eco-friendly alternatives that reduce reliance on fossil fuels.

Lactips specializes in the production of water-soluble and biodegradable thermoplastic pellets made from milk protein. Utilizing a proprietary industrial process, the company delivers these pellets in high volumes to serve as raw materials for various applications, including thermoforming and film production. Lactips aims to provide its industrial clients with innovative solutions that facilitate entry into new markets while promoting sustainability. Their products offer a cleaner alternative to traditional oil-based plastics, contributing to a more environmentally friendly approach to material use by enhancing dissolution in both hot and cold water.

Biolevate is an AI-driven company focused on enhancing healthcare research and patient care. It offers IT consulting services, employing advanced AI algorithms to streamline research workflows. The company's platform automates tasks such as document generation and literature monitoring, intelligently filtering vast datasets to provide relevant, actionable scientific information. It offers customizable search options and insightful data visualizations, empowering clients to make informed decisions and accelerate scientific breakthroughs, ultimately improving patient care.

FairCraft is a company focused on creating a sustainable alternative to traditional animal leather through innovative synthetic biology and material science techniques. By utilizing cellular culture, tissue engineering, and advanced material science, FairCraft develops lab-grown leather that provides a slaughter-free option for the fashion industry. This approach not only aims to reduce CO2 emissions associated with conventional leather production but also ensures high mechanical strength and durability for consumers. Through its commitment to sustainability and cutting-edge technology, FairCraft is positioned to transform the leather market by offering environmentally friendly solutions.

Primaa is a MedTech company that specializes in developing an AI-based platform for the automated and accurate diagnosis of cancer. The company's innovative software utilizes image analysis and deep learning techniques to improve the detection of key cancer biomarkers. By digitizing histological slides and compiling images into a comprehensive database, Primaa's technology allows medical professionals to efficiently identify tissue damage and conduct a growing number of diagnoses with a high degree of reliability. This approach not only enhances diagnostic accuracy but also supports personalized treatment plans for patients.

Elicit Plant is an agro-biotech company focused on enhancing the resilience of crops to water stress and developing phytosterol-based solutions. By leveraging proprietary technology, Elicit Plant aims to address the challenges posed by climate change on agriculture. The company’s products are designed to improve plant stress resistance and activate natural defenses, which has been validated through extensive field trials across three continents. These trials demonstrate that Elicit Plant's biosolutions provide farmers with consistent and significant returns on investment, positioning the company as a leader in the ecological transition within the agricultural sector.

Fudzs is a pioneer in the sustainable bioeconomy, specializing in the development of eco-friendly cell bioproduction processes utilizing advanced bioreactor technology. The company focuses on the mass production of cells through innovative biomaterial engineering combined with cellular science, which enables cost-effective solutions for various industries. Fudzs aims to revolutionize the cultivated meat sector by creating affordable and high-quality meat alternatives, as well as enhancing cell therapies. Its proprietary approach to biomaterials is optimized for cell growth, significantly increasing cell amplification and density in bioreactors, thereby unlocking new market opportunities and promoting a more sustainable future in food production and healthcare.

Vaxinano is a biotechnology company focused on the preclinical and pharmaceutical development of vaccines and drug delivery systems for both humans and animals. Established in 2016, Vaxinano builds on 25 years of research and clinical trials related to vaccines, utilizing the patented technology of Pr Didier Betbeder. The company specializes in creating safe-by-design nanoparticles that adhere to green chemistry principles, which support the development of prophylactic and therapeutic vaccines for infectious diseases. Additionally, Vaxinano aids medical researchers in formulating drugs that activate biomolecules, proteins, and antigens, thereby facilitating innovative approaches to combat untreated viral, bacterial, and parasitic diseases.

Starfish Bioscience specializes in developing microbiological solutions for agriculture and vineyards, aiming to regenerate soils by restoring their microbiomes. The company provides analysis of soil microbiomes and creates innovative solutions to enhance soil health and crop yields. By focusing on sustainability and productivity, Starfish Bioscience seeks to minimize environmental impact and address future challenges in global agriculture, ultimately contributing to the well-being of humanity and the preservation of the Earth.

Okomera is a biotech start-up focused on enhancing the development of precision-based cancer medicines. The company specializes in automating and streamlining individualized tumor biopsy research through innovative medical technologies. By utilizing microfluidic 3D cellular assays, Okomera's approach allows for the prediction of patient-specific responses to therapies. This is achieved by cultivating cells within thousands of microfluidic droplets and exposing them to various conditions in parallel, which accelerates the process of biologically relevant biopsy testing. Consequently, Okomera's technologies enable healthcare providers to expedite cancer treatment, ultimately improving patient outcomes.

Vetbiolix is a veterinary biotechnology company dedicated to developing innovative therapeutic solutions for dogs and cats. The company focuses on creating first-in-class drug candidates aimed at treating and preventing diseases that affect pets, particularly in areas such as periodontitis, osteoarthritis, and gut motility disorders. By emphasizing clinical development, Vetbiolix strives to offer effective treatments for common health issues in pets, ultimately enhancing their quality of life.

Enalees is a biotechnology company focused on developing molecular diagnostic tests specifically for pets. The company has created a platform that enables veterinarians to quickly identify microbes responsible for infectious diseases in leisure animals, such as horses. By providing DNA tests that can detect infections, Enalees facilitates timely diagnosis in veterinary clinics, allowing for more effective treatment of animal pathologies. This innovative approach aims to enhance the veterinary diagnostic process and improve animal health outcomes.

Micropep Technologies is an agricultural biotechnology firm based in Toulouse, France, founded in 2016. The company specializes in developing non-GMO bioherbicides and biostimulants through its proprietary miPEP technology, which utilizes naturally-occurring micro-peptides to regulate gene expression and enhance plant growth. Micropep's approach allows for the temporary control of gene expression without altering the plant's DNA, focusing on optimizing various stages of plant development, including germination, flowering, growth, and weed control. By leveraging these innovative solutions, Micropep aims to improve agricultural yields and support sustainable farming practices.

Genomines focuses on sustainable mining by utilizing genetically enhanced hyperaccumulator plants to extract critical metals from soil. By leveraging synthetic biology, the company enhances the natural capacity of these plants to absorb metals, which not only allows for the recovery of valuable resources but also contributes to soil depollution and increases agricultural land availability. This approach addresses the growing demand for metals essential for clean energy technologies while mitigating the environmental and social challenges associated with traditional mining practices. Genomines aims to create a more responsible and sustainable pathway for metal extraction, aligning with global efforts to transition to greener energy solutions.

Starkage Therapeutics is a discovery-stage biotechnology company focused on improving the quality of life for patients suffering from various health conditions. The company is developing a platform that targets the depletion of senescent cells, which are linked to age-related diseases, through a combination of immunotherapy and cancer treatment approaches. Starkage Therapeutics aims to address unmet medical needs in areas such as idiopathic pulmonary fibrosis, neurodegenerative diseases, and metabolic dysfunction or hepatic fibrosis. Through its innovative research and therapeutic strategies, the company seeks to enhance patient health and treatment outcomes.

Biodol Therapeutics SAS, founded in 2015 and located in Clapiers, France, focuses on developing innovative treatments for chronic pain. The company has identified the receptor tyrosine kinase FLT3 as a critical factor in triggering and sustaining chronic neuropathic pain. Through its proprietary approach, Biodol Therapeutics develops extracellular inhibitors of the FLT3 receptor, which aim to inhibit ligand binding and thereby alleviate conditions such as allodynia, pain hypersensitivity, and spontaneous pain without disrupting normal nervous system function. Additionally, research partnerships have indicated that inhibiting FLT3 may enhance the efficacy of opioids, potentially reducing their associated risks, including addiction. This innovative work positions Biodol Therapeutics as a significant player in addressing chronic pain and contributing to solutions for the opioid crisis.

MaaT Pharma is a clinical-stage biotechnology company based in Lyon, France, founded in 2014. It specializes in developing therapies aimed at treating diseases associated with gut microbiota imbalance, particularly in the context of cancer and Graft-versus-Host Disease, a complication related to stem cell transplantation. The company has made significant advancements in its research, achieving proof of concept in patients with acute myeloid leukemia. MaaT Pharma employs a comprehensive approach to restore microbiome symbiosis, which has implications for enhancing survival outcomes in life-threatening conditions. Additionally, it has developed a proprietary platform called GutPrint®, which is instrumental in evaluating drug candidates and identifying biomarkers for microbiome-related diseases, thereby supporting the expansion of its therapeutic pipeline, including improvements in immunotherapy for solid tumors.

Hephaistos Pharma is a biotechnology company focused on advancing oncology treatments through innovative immunotherapy solutions. The firm develops a platform that utilizes active and non-specific immuno-stimulants to enhance the effectiveness of existing antibodies by transforming cold tumors into hot targets, which can significantly improve patient outcomes. This approach aims to address unmet medical needs in cancer treatment, enabling patients to tackle previously incurable cancers. Hephaistos Pharma is dedicated to elevating immunotherapy efficiency by stimulating immune responses, thereby offering new hope in the fight against cancer. Interested parties can access more information through an online inquiry form available on the company's website.

Tribun Health is a company focused on transforming cancer detection through innovative diagnostic imaging software. Its solutions enable diagnostic laboratories and the pharmaceutical and biotech sectors to effectively manage, analyze, and share cellular images. By offering digital microscopy-like analysis along with macroscopic imaging capabilities, Tribun Health enhances the accuracy of diagnostics and scientific evaluations related to patient cells and tissues. The company's technology aims to streamline the workflow in laboratories, facilitating better collaboration and data sharing among healthcare professionals.

SeaBeLife Biotech SAS is a biotechnology company based in Roscoff, France, established in 2019. The company focuses on developing innovative drug candidates aimed at treating acute pathologies, particularly acute liver and renal failure. SeaBeLife's products are derived from a family of patented molecules designed to block regulated necrosis, a type of regulated cell death. By targeting two synergistic pathways involved in various acute and chronic diseases, SeaBeLife aims to establish a new standard of care for patients with significant unmet medical needs. Through its research and development efforts, the company seeks to enhance patient outcomes and reduce complications associated with serious health conditions.

Surge is a biotechnology company dedicated to enhancing surgical outcomes for patients. It has developed an advanced immunological model known as Surge2surgery, which predicts postoperative infections. This innovative platform integrates a single-cell analysis of the immune system conducted prior to surgery with clinical data, utilizing a proprietary machine-learning algorithm. By examining millions of immune cells from a small blood sample, Surge's technology simulates surgical trauma in a controlled environment, allowing for improved predictions and potentially better patient care.

ABIONYX Pharma SA is a French biopharmaceutical company established in 2005, currently based in Labege. It specializes in the discovery and development of therapies targeting high-density lipoprotein (HDL) for treating cardiovascular and metabolic diseases. The company's primary focus is on developing HDL mimetics to rapidly regress atherosclerotic plaque in high-risk patients. Its lead product candidate, CER-001, is a Phase II clinical trial asset designed to mimic the properties of pre-beta HDL for treating post-acute coronary syndrome patients and familial primary hypoalphalipoproteinemia patients. Additionally, ABIONYX Pharma has another drug candidate, CER-209, in Phase I trials for metabolic diseases and liver-related conditions such as atherosclerosis and non-alcoholic steato-hepatitis.

HawkCell is a medical research company specializing in advanced magnetic resonance imaging (MRI) solutions for veterinary clinics and preclinical research laboratories. The company utilizes a non-ionizing three-dimensional (3D) imaging approach, employing specialized MRI sensors designed to accommodate various animal morphologies. By adapting human MRI technology for animal diagnostics, HawkCell provides sustainable systems enhanced with artificial intelligence algorithms. This innovation allows veterinary clinics and research labs to obtain precise and insightful imaging, facilitating improved animal healthcare and scientific exploration.

Bioptimus specializes in the development of a universal artificial intelligence foundation model aimed at enhancing scientific research and biotechnological innovation. The company's technology seamlessly connects various scales of biology, ranging from molecules to cells, tissues, and entire organisms. By transforming multiscale data into actionable representations, Bioptimus enables its clients to drive breakthrough discoveries and accelerate advancements in the biomedical field.

Okomera is a biotech start-up focused on enhancing the development of precision-based cancer medicines. The company specializes in automating and streamlining individualized tumor biopsy research through innovative medical technologies. By utilizing microfluidic 3D cellular assays, Okomera's approach allows for the prediction of patient-specific responses to therapies. This is achieved by cultivating cells within thousands of microfluidic droplets and exposing them to various conditions in parallel, which accelerates the process of biologically relevant biopsy testing. Consequently, Okomera's technologies enable healthcare providers to expedite cancer treatment, ultimately improving patient outcomes.

Eligo Bioscience S.A.S is a biotechnology company based in Paris, France, that specializes in the development of Eligobiotics, a new class of antimicrobials designed to target specific bacteria based on their genetic makeup. Founded in 2014, the company utilizes a combination of CRISPR/Cas technology and engineered phage capsids to create antibiotics capable of addressing microbiome-related diseases and combating resistant pathogens. These programmed antimicrobials aim to eradicate virulent bacteria within the human microbiome, facilitating the creation of advanced therapeutics for conditions caused by superbugs. Eligo Bioscience's innovative approach positions it at the forefront of microbiome precision therapies and next-generation antibiotic solutions.

GenSight Biologics S.A. is a clinical-stage biotechnology company based in Paris, France, focused on developing gene therapy treatments for retinal degenerative diseases and neurodegenerative conditions affecting the central nervous system. Utilizing its core technology platforms—Mitochondrial Targeting Sequence and Optogenetics—the company aims to preserve and restore vision in patients with severe retinal disorders. Its lead product candidates include GS010, an AAV2-based gene therapy currently in Phase III trials for treating Leber hereditary optic neuropathy caused by mutations in the ND4 gene, and GS030, which is undergoing Phase I/II trials for retinitis pigmentosa and geographic atrophy in dry age-related macular degeneration. In addition to these, GenSight is advancing several products in preclinical stages targeting various ophthalmic and neurodegenerative diseases. Founded in 2012, the company is dedicated to innovative approaches that aim to prevent vision loss and improve the quality of life for affected patients.

Nouscom is a biotechnology company focused on developing an immunotherapy platform that creates modified viral vector vaccines for cancer treatment. The company utilizes a range of engineered viral vectors optimized for the effective expression of long strings of tumor neoantigens. Additionally, its platform includes tools designed to induce broad and potent antitumor T-cell responses, which aim to enhance cancer-specific cellular immunity in patients.

Astraveus is transforming cell and gene therapy (CGT) manufacturing through its Lakhesys™ platform, an innovative cell foundry that leverages deep process optimization and microfluidic bioprocessors. This technology allows for the production of personalized biological therapies with minimal infrastructure requirements, ultimately reducing costs and addressing logistical challenges in the industry. By automating autologous bioproduction, the platform enhances the efficiency of transforming cells into therapeutic agents, enabling healthcare providers to scale the development and manufacturing of CGT solutions. Astraveus aims to improve patient access to these vital therapies while minimizing environmental impact.

Injectpower specializes in developing energy storage technologies and micro-batteries tailored for medical implants. Their core product is a small, solid-state battery that powers implantable devices, enabling them to function as sensors or actuators for extended periods without the need for recharging. With over 16 years of research and 40 patents, Injectpower's batteries are manufactured using a proven semiconductor supply chain, ensuring high reliability. The company's innovative solutions include batteries for devices that monitor intraocular pressure in glaucoma patients and intracranial pressure and fluid flow, allowing physicians to remotely monitor and diagnose conditions more effectively.

Global Bioenergies SA specializes in developing a biological process that converts renewable resources into isobutene, a crucial petrochemical building block used in fuels, plastics, organic glass, and elastomers. The company, based in Evry, France, is notable for being one of the few globally and the only one in Europe focusing on this innovative fermentation technology. It operates an industrial pilot plant and is nearing the completion of a demonstration plant in Germany, alongside preparing for its first full-scale production facility in collaboration with Cristal Union, known as IBN-One. In addition to isobutene, Global Bioenergies has expanded its capabilities to include the production of propylene and butadiene, both vital components in the petrochemical sector. The company was founded in 2008 and continues to enhance the efficiency of its processes while offering engineering services related to gas fermentation.

Global Bioenergies SA specializes in developing a biological process that converts renewable resources into isobutene, a crucial petrochemical building block used in fuels, plastics, organic glass, and elastomers. The company, based in Evry, France, is notable for being one of the few globally and the only one in Europe focusing on this innovative fermentation technology. It operates an industrial pilot plant and is nearing the completion of a demonstration plant in Germany, alongside preparing for its first full-scale production facility in collaboration with Cristal Union, known as IBN-One. In addition to isobutene, Global Bioenergies has expanded its capabilities to include the production of propylene and butadiene, both vital components in the petrochemical sector. The company was founded in 2008 and continues to enhance the efficiency of its processes while offering engineering services related to gas fermentation.

Diamidex SAS, established in 2014 and based in Marseille, France, specializes in the development and production of rapid detection tests for legionella, a type of bacteria that can cause severe lung infections. The company offers turnkey test solutions, designed for both laboratory and field use, which provide a semi-quantitative count of microorganisms in water samples and industrial goods. Diamidex's products aim to enhance the accuracy of microbial contamination detection, facilitating quicker experimentation and data collection in research labs.

EverImmune is focused on developing innovative biotherapeutic products aimed at treating cancer patients through microbiome oncology. The company specializes in creating live biotherapeutic products (LBP) that serve as oral adjuvants to enhance anticancer immunotherapies. By leveraging technology to safely boost the immune system and restore sensitivity to immunotherapies, EverImmune seeks to improve the effectiveness of cancer treatments, particularly in cases of primary resistance. The firm plans to conduct well-designed clinical trials to test its lead product, Oncobax®, as part of its commitment to advancing cancer care.

Toopi Organics SAS is a biotechnology company based in Langon, France, that specializes in the collection and upcycling of human urine to create biostimulants for agriculture. Founded in 2019, the company develops products like Arbop and Vitip, which support plant growth by serving as natural alternatives to chemical fertilizers. Toopi Organics employs microbiological technology to enhance and enrich human urine, providing an environmentally friendly solution for the agricultural community. By transforming waste into valuable resources, the company aims to offer economical and efficient options for sustainable farming practices.

Tribun Health is a company focused on transforming cancer detection through innovative diagnostic imaging software. Its solutions enable diagnostic laboratories and the pharmaceutical and biotech sectors to effectively manage, analyze, and share cellular images. By offering digital microscopy-like analysis along with macroscopic imaging capabilities, Tribun Health enhances the accuracy of diagnostics and scientific evaluations related to patient cells and tissues. The company's technology aims to streamline the workflow in laboratories, facilitating better collaboration and data sharing among healthcare professionals.

Phagos is a biotechnology company focused on developing personalized bacteriophage solutions as a sustainable alternative to traditional antibiotics. The company operates a research platform that creates customizable drugs aimed at replacing antibiotics in animal farming. By harnessing bacteriophages, which are natural predators of bacteria, Phagos seeks to provide an effective means to combat incurable and deadly infectious diseases. This innovative approach aligns with the growing need for alternatives to antibiotics in both human and veterinary medicine, addressing health challenges while promoting sustainable practices in agriculture.

BioMAdvanced Diagnostics focuses on developing molecular diagnostic and biomarker tests that enhance patient care by integrating seamlessly into existing diagnostic and treatment protocols. The company's tests are designed to be user-friendly for healthcare personnel and economically accessible. By providing predictive scores and identifying biomarkers, these tests assist clinicians in evaluating and diagnosing the risk of transplant rejection, thereby enabling more effective and individualized treatment strategies. This approach aims to significantly improve patient outcomes by equipping physicians with advanced tools to monitor and manage their patients' immune responses.

GenSensor is a biotechnology company that specializes in developing and implementing a genomic-based, in-line bioproduction monitoring system. This system combines a robotic device with advanced analytics software to monitor, characterize, and optimize the production of advanced therapy medicinal products (ATMPs) and vaccines. By providing real-time insights into the bioproduction process, GenSensor helps healthcare companies maximize the use of innovative drugs, improve production efficiency, and ultimately reduce manufacturing costs, thereby benefiting patients.

Numa Health is a medical bioinformatics company that develops a digital health platform aimed at helping individuals optimize their health and well-being. The platform offers tools that reinterpret blood test results, providing users with insights into their body's functioning. By delivering accessible health information, Numa Health enables individuals to measure, understand, and take action regarding their health, fostering a greater commitment to personal health management.

Veragrow is a biotechnology company that specializes in the production of organic fertilizers and biostimulants through the process of vermicomposting agricultural waste. By recovering organic waste from agriculture, livestock, and the food industry, Veragrow offers sustainable alternatives to chemical fertilizers. Their products are designed to enhance soil health and promote ecological balance, providing revitalizing properties that help increase yields in organic farming. This approach not only supports agricultural productivity but also aligns with environmentally friendly practices.

Kairos Discovery is a biotechnology company focused on developing innovative targeted cancer therapies. The company aims to create medicinal chemistry solutions that address key cellular mechanisms responsible for the survival and aggressiveness of both solid tumors and hematological cancers. By utilizing a first-in-class approach, Kairos Discovery seeks to provide breakthrough technology in oncology, ultimately improving the lives of cancer patients and their families.

Ynsect is a biotechnology company based in Evry, France, that specializes in the production and processing of insects for sustainable animal feed and non-food applications. Founded in 2011, Ynsect operates insect vertical farms that convert insects into high-quality nutrition products, including proteins and lipids for livestock and pet diets. The company employs innovative bioconversion techniques to utilize organic resources, producing not only animal feed but also organic fertilizers, bioenergy, and other valuable materials. Ynsect's expertise in large-scale insect farming and automation has positioned it as a leading provider in the agro-food and environmental biotech sectors, making it a favored partner for agricultural professionals, research institutions, and investors.

Odimma is a biotech company specializing in precision medicine aimed at developing personalized cancer immunotherapy solutions. The company has created an innovative immunotherapy drug that harnesses a unique platform, integrating three specific immune components designed to work together with the patient's immune system. When administered, this approach aims to induce and enhance immune responses, providing patients with the potential to eliminate tumors while minimizing adverse side effects. Through its focus on personalized treatment strategies, Odimma seeks to improve outcomes for cancer patients by tailoring therapies to individual needs.

Alentis Therapeutics AG is a clinical-stage biopharmaceutical company based in Basel, Switzerland, focused on developing innovative therapies for advanced liver diseases, including liver fibrosis, cirrhosis, and liver cancer. Established in 2019, Alentis is recognized for its pioneering work in targeting CLDN1+ cancers through the use of anti-CLDN1 antibody-drug conjugates and other therapeutic modalities. The company's research platform incorporates clinically relevant read-outs and single-cell RNA sequencing of patient liver tissues, which aids in understanding and treating fibrotic diseases. Alentis aims to modify and reverse disease progression, ultimately addressing significant health challenges associated with liver-related conditions.

Hemerion is a biotechnology company dedicated to developing innovative cancer treatments, specifically targeting glioblastoma, the most prevalent and aggressive primary brain tumor. The company operates a platform that integrates therapeutic services at the intersection of surgery and photonics, utilizing a photosensitizing drug for a drug-device combination therapy. This approach enables healthcare professionals to selectively destroy cancer cells in regions that are difficult to access through traditional surgical methods, all while preserving healthy tissues. Hemerion's focus on advanced treatment options aims to enhance the healthcare industry's ability to combat brain cancer and improve patient outcomes in the fight against glioblastoma.

Kayentis is a global leader in electronic clinical outcome assessment (eCOA) and decentralized clinical trial solutions, dedicated to enhancing data collection processes in clinical trials for the pharmaceutical, biotech, and contract research organization sectors. Founded in 2005, the company has developed expertise in eCOA solutions applicable across all phases of clinical development, addressing over 200 indications in more than 20 therapeutic areas. To meet the evolving demands of clinical research, Kayentis offers a comprehensive suite of services that prioritize scientific integrity and patient-centric approaches. With operational capabilities spanning the USA, Europe, and Asia, the company's technology facilitates electronic data capture, providing a versatile range of tools designed to simplify data collection for both patients and clinical trial sites.

Genomines focuses on sustainable mining by utilizing genetically enhanced hyperaccumulator plants to extract critical metals from soil. By leveraging synthetic biology, the company enhances the natural capacity of these plants to absorb metals, which not only allows for the recovery of valuable resources but also contributes to soil depollution and increases agricultural land availability. This approach addresses the growing demand for metals essential for clean energy technologies while mitigating the environmental and social challenges associated with traditional mining practices. Genomines aims to create a more responsible and sustainable pathway for metal extraction, aligning with global efforts to transition to greener energy solutions.

AlgoTherapeutix is a biotechnology company focused on developing topical treatments for complex pain conditions, particularly those that are difficult to treat and lack proven therapies. The organization targets damaged nerve fibers in the skin, aiming to provide pain relief without the systemic side effects associated with oral medications. Currently, AlgoTherapeutix's lead product, ATX01, has received FDA approval to enter Phase 2 clinical trials for chemotherapy-induced peripheral neuropathy, a painful condition resulting from cancer treatment. Additionally, the company is exploring the potential of its treatments for erythromelalgia, a rare and debilitating disorder characterized by severe pain. Through its innovative approach, AlgoTherapeutix seeks to address the specific needs of patients suffering from these challenging conditions.

PILI Inc. is a company based in Paris, France, that specializes in researching and manufacturing bio-fabricated colors derived from microorganisms. Founded in 2012, the company focuses on designing enzymes and fermentation biotechnologies that convert sugar into sustainable and long-lasting dyes and pigments. PILI produces renewable inks as an eco-friendly alternative to traditional toxic and non-recyclable options. The company emerged from a collaboration among a biologist, a designer, and a financial analyst in a biohacker space, leading to the creation of innovative products like a pen fed by bacteria. By utilizing microorganisms, PILI aims to replace petrochemical and non-sustainable vegetable dyes, promoting sustainable development while also helping businesses reduce costs.

NFL Biosciences is a biotechnology company focused on developing solutions for tobacco addiction. The company specializes in researching and creating medicines that utilize both botanical and pharmaceutical agents to assist smokers in their efforts to quit. Its primary product, NFL-101, is a clinically developed botanical drug designed to target smoking addiction. NFL-101 contains a minimal amount of nicotine and is formulated from well-characterized natural tobacco leaf proteins, offering a novel approach to support individuals in overcoming their dependence on tobacco.

BiPER Therapeutics is a biotechnology company focused on developing and commercializing innovative therapeutics. The company specializes in creating drugs that target critical proteins involved in the metabolism of cancer cells, aiming to address treatment resistance and enhance cancer cell survival. Its therapeutic offerings are particularly aimed at the treatment of gastrointestinal cancers, providing potential solutions for patients facing these challenging conditions.

Ecoat develops bio-based chemistries tailored for the coatings industry, focusing on sustainable solutions. The company offers a range of water-based, bio-based products, including bio-based alkyd emulsions, acrylics, and specialty oils. Its product lineup features innovative offerings such as secoia, inokem, air purifying emulsions, and solkem, all designed to promote environmental sustainability within the paint and coating sector. By emphasizing the adoption of eco-friendly materials, Ecoat aims to facilitate the industry's transition towards more sustainable practices.

NFL Biosciences is a biotechnology company focused on developing solutions for tobacco addiction. The company specializes in researching and creating medicines that utilize both botanical and pharmaceutical agents to assist smokers in their efforts to quit. Its primary product, NFL-101, is a clinically developed botanical drug designed to target smoking addiction. NFL-101 contains a minimal amount of nicotine and is formulated from well-characterized natural tobacco leaf proteins, offering a novel approach to support individuals in overcoming their dependence on tobacco.

Mycophyto, co-founded in July 2016 by microbiologist Justine Lipuma and Senior Research Engineer Christine Poncet-Doise, specializes in biological crop protection based on three decades of research. The company develops customized products and offers specific support services to facilitate innovative agricultural systems. Mycophyto's plant production system focuses on identifying indigenous fungi and beneficial soil pathogens that enhance plant growth. By cultivating these microorganisms in an integrated greenhouse, the company enables researchers to grow a variety of plants, crops, and herbs sustainably, reducing dependence on chemical fertilizers. Through its unique approach, Mycophyto aims to advance agricultural practices while promoting environmental sustainability.

ErVaccine Technologies creates immunotherapies that integrate T-cell treatments with cancer vaccinations to meet a medical need for cold tumors. They are committed to identifying tumor epitopes that are physician. They come from endogenous retroviruses and are novel cancer epitopes. They use a bioinformatics-based strategy to find possible epitopes, which are then verified by proteomics and immunological testing.

Remedee Labs SAS is a French company founded in 2016, specializing in the research and development of a personal endorphin stimulator aimed at pain management. The company has created the Microelectronic Endorphin Trigger (MEET), a device designed to stimulate the release of the body’s own endorphins on demand. This innovative technology is particularly focused on helping individuals suffering from chronic pain conditions, with an initial emphasis on fibromyalgia. Remedee Labs has developed a patient-centered digital service platform that collaborates with medical practitioners to enhance chronic pain management. Backed by a decade of pre-clinical and clinical research, the company aims to provide a new approach to pain relief for the 1.5 billion people worldwide affected by chronic pain, many of whom are dissatisfied with existing treatment options. In 2019, Remedee Labs secured significant funding from various investors to further its mission of making endorphin-stimulation therapy accessible and effective for personal healthcare.

Jalon Therapeutics is focused on developing innovative therapies that target essential tumor signaling pathways that have not yet been addressed. The company aims to transform the lives of cancer patients by creating medicines that effectively inhibit these pathways. Through its research, Jalon Therapeutics explores the potential of non-oncogene addiction to discover new therapeutic targets and develop groundbreaking anticancer treatment strategies. The company's work is centered on improving treatment options for individuals battling cancer, ultimately striving to enhance their quality of life.

Microphyt specializes in the research, development, production, and marketing of natural algae-based products aimed at enhancing health and wellness. The company focuses on creating bioactive dietary supplements that support weight loss and brain health. Utilizing an industrial-scale supply of microalgae biomass and extracts, Microphyt ensures the preservation of cell integrity while producing commercial quantities of slow-growing or biofilm-forming species. This approach enables the healthcare industry to effectively meet the demands of personal care and food products, positioning Microphyt as a key player in the market for natural health solutions.

Meccellis Biotech SAS, founded in 2013 and based in La Rochelle, France, specializes in developing biologic implants using acellular dermis. The company focuses on tissue and cell engineering to create biological implants that facilitate tissue repair across various surgical specialties. Their product offerings include Cellis and Cellis breast implants, designed to address specific clinical needs during surgical procedures, such as abdominal wall repair. By maintaining continuous communication with surgeons, Meccellis Biotech aims to provide tailored solutions that meet the evolving demands of the medical field.

Biomemory is a deep-tech company focused on advanced data storage solutions for large enterprises and organizations. It specializes in molecular engineering to create innovative, bio-based data storage drives that utilize long DNA strands for data retention. This approach offers a cost-effective and energy-efficient alternative to traditional storage methods such as solid-state drives and magnetic tape. Biomemory's technology allows for the stable storage of vast amounts of data at ambient temperatures without requiring energy input or generating CO2 emissions. As a result, its storage media are designed to be durable for thousands of years, providing a sustainable solution for the growing demands of data centers.

Lys Therapeutics is a biotechnology company focused on developing therapies for patients with neurovascular and neurodegenerative disorders. The company is centered around its lead product, Glunozumab, a monoclonal antibody that operates through a unique mechanism of action. This drug induces off-target toxicity by hyperactivating vascular and neuronal NMDA receptors, which can lead to significant disruptions in the blood-brain and blood-spinal cord barriers, as well as neuronal excitotoxicity. These effects are particularly relevant in conditions such as stroke and multiple sclerosis, where the modulation of neuroinflammation is critical for treatment.

BioMAdvanced Diagnostics focuses on developing molecular diagnostic and biomarker tests that enhance patient care by integrating seamlessly into existing diagnostic and treatment protocols. The company's tests are designed to be user-friendly for healthcare personnel and economically accessible. By providing predictive scores and identifying biomarkers, these tests assist clinicians in evaluating and diagnosing the risk of transplant rejection, thereby enabling more effective and individualized treatment strategies. This approach aims to significantly improve patient outcomes by equipping physicians with advanced tools to monitor and manage their patients' immune responses.

Tridek-One is a biotechnology company focused on developing immunomodulatory products aimed at treating autoimmune diseases and inflammatory disorders. The company has created a peptide that preserves a cluster of truncated CD31 molecules at the membrane, allowing for the moderation of overactive immune responses without complete blockade. This innovative approach enables medical companies to provide enhanced therapeutic options, ultimately improving patient outcomes and quality of life.

SparingVision SAS is a biotechnology company based in Paris, France, dedicated to discovering and developing gene therapy-based treatments for inherited retinal diseases that can lead to blindness. Founded in 2016, the company is focused on creating innovative therapies for conditions such as retinitis pigmentosa, the most prevalent form of inherited retinal degeneration, which currently lacks comprehensive treatment options. SparingVision is advancing its lead candidate, SPVN06, which aims to address the needs of the nearly 2 million individuals affected by this rare genetic disorder globally. By targeting the underlying causes of these diseases, SparingVision seeks to improve the quality of life for patients suffering from genetic retinal disorders.

Apmonia Therapeutics is focused on developing next-generation peptide-based therapies aimed at improving treatment options for various types of cancer, including glioblastoma, ovarian, colorectal, and pancreatic cancers. The company concentrates on targeting the tumor microenvironment, which plays a crucial role in cancer progression. By creating innovative drugs, Apmonia Therapeutics seeks to enhance therapeutic strategies for solid tumors and provide new perspectives in cancer treatment. Their approach includes the development of personalized immunotherapy solutions that utilize proprietary therapeutic peptides, ultimately aiming to improve the quality of life for patients battling cancer and assisting researchers in their efforts to advance cancer therapies.

Carroucell specializes in providing microcarriers for cell culture in bioreactors. The company has developed a unique microscopic matrices platform that features flat-shaped microcarriers made from a glass xenofree composition. This innovative design aims to enhance the efficiency of biomanufacturing processes by addressing common performance challenges associated with traditional cell culture methods. Carroucell's products are tailored to meet the needs of customers in the biopharmaceutical industry, facilitating improved outcomes in cell culture applications.

DeepLife is a biotech company based in Paris, France, founded in 2019. It focuses on developing digital twins of cells to enhance drug discovery processes. By utilizing deep learning techniques on multi-omics data, DeepLife models cellular behavior and simulates responses to various genetic screenings, such as siRNA and CRISPR-Cas9. This approach allows the identification of new drug targets, biomarkers, and potential drug candidates, enabling a better understanding of drug resistance and sensitivity. The company's mission is to advance systems biology and facilitate the transition of laboratory discoveries to clinical applications. DeepLife collaborates with academic institutions to leverage expertise and drive innovation in the biopharmaceutical industry, ultimately aiming to match the right drug to the right patient.

Øzers is a French foodtech company that specializes in creating innovative sports nutrition products using only healthy, vegan ingredients. Founded by a professional boxer and an engineer, the company collaborates with biotech engineers and medical professionals to develop its offerings. Øzers focuses on enhancing athletic performance without compromising health, providing ultra-functional edible supplements made from plant-based ingredients, including vegetable proteins, microalgae, vitamins, and minerals. By utilizing the potential of these natural components, Øzers aims to support athletes in achieving their maximum performance.

Thabor Therapeutics is a biotechnology company focused on developing innovative treatments for mucosal inflammatory diseases. The company targets a new class of proteins involved in the resolution of inflammation, utilizing monoclonal antibodies to address these conditions. By inhibiting specific targets implicated in early inflammatory processes and the recruitment of innate immune cells, Thabor Therapeutics aims to provide effective therapies that enable healthcare providers to improve patient outcomes.

Phagos is a biotechnology company focused on developing personalized bacteriophage solutions as a sustainable alternative to traditional antibiotics. The company operates a research platform that creates customizable drugs aimed at replacing antibiotics in animal farming. By harnessing bacteriophages, which are natural predators of bacteria, Phagos seeks to provide an effective means to combat incurable and deadly infectious diseases. This innovative approach aligns with the growing need for alternatives to antibiotics in both human and veterinary medicine, addressing health challenges while promoting sustainable practices in agriculture.

Healshape is a biotech startup dedicated to developing natural breast reconstruction solutions for women. The company specializes in regenerative medicine, focusing on creating innovative alternatives for breast regeneration through advanced 3D bioprinting technology. Healshape's primary product is a bioprosthesis designed for breast reconstruction, which aims to empower women by helping them regain self-confidence and achieve long-lasting, aesthetically pleasing results following surgery.

Osivax is a company focused on developing immunotherapy vaccines aimed at treating infectious diseases. Its innovative vaccines enhance the uptake into dendritic cells and boost the immunogenicity of natural proteins, which triggers a more effective immune response, particularly through significant CD8 T cell activation. This technology is designed to serve as a universal vaccine, targeting not only existing but also emerging coronavirus infections, as well as other globally impactful infectious diseases. In addition to infectious diseases, Osivax's vaccines also support cancer treatment, providing medical practitioners with advanced tools to treat a range of serious health conditions effectively.

DBV Technologies S.A. is a clinical-stage biopharmaceutical company based in Montrouge, France, dedicated to developing epicutaneous immunotherapy products aimed at treating food allergies. The company's lead candidate, Viaskin Peanut, has completed Phase III clinical trials for peanut allergies in children and adults. Additionally, DBV is developing Viaskin Milk, currently in Phase I/II trials for cow's milk protein allergy and related conditions, and Viaskin Egg, which is in pre-clinical stages for hen's egg allergy. The company also works on a booster vaccine for Bordetella pertussis and has earlier-stage research programs targeting respiratory syncytial virus, Crohn's disease, celiac disease, and type I diabetes. DBV Technologies collaborates with Nestlé Health Science to create MAG1C, a diagnostic patch test for non-IgE mediated cow's milk protein allergy in infants and toddlers. Founded in 2002, the company aims to provide safe and effective treatments for food allergies through its innovative Viaskin technology platform, which delivers biologically active compounds via the skin to activate the immune system.

Hemerion is a biotechnology company dedicated to developing innovative cancer treatments, specifically targeting glioblastoma, the most prevalent and aggressive primary brain tumor. The company operates a platform that integrates therapeutic services at the intersection of surgery and photonics, utilizing a photosensitizing drug for a drug-device combination therapy. This approach enables healthcare professionals to selectively destroy cancer cells in regions that are difficult to access through traditional surgical methods, all while preserving healthy tissues. Hemerion's focus on advanced treatment options aims to enhance the healthcare industry's ability to combat brain cancer and improve patient outcomes in the fight against glioblastoma.

Ribonexus is a biotechnology company dedicated to developing innovative therapies aimed at treating cancer, particularly melanoma. The company is focused on creating a pipeline of small molecules that target the eukaryotic translation Initiation Factor-4A (eIF4A), which plays a significant role in various solid and hematologic cancers. This target is particularly relevant for addressing resistance to existing treatments, which often diminishes the effectiveness of targeted therapies. Ribonexus aims to produce drugs that can restore sensitivity to these therapies in patients who have developed resistance, thereby improving treatment outcomes in oncology.

Ribonexus is a biotechnology company dedicated to developing innovative therapies aimed at treating cancer, particularly melanoma. The company is focused on creating a pipeline of small molecules that target the eukaryotic translation Initiation Factor-4A (eIF4A), which plays a significant role in various solid and hematologic cancers. This target is particularly relevant for addressing resistance to existing treatments, which often diminishes the effectiveness of targeted therapies. Ribonexus aims to produce drugs that can restore sensitivity to these therapies in patients who have developed resistance, thereby improving treatment outcomes in oncology.

Phagos is a biotechnology company focused on developing personalized bacteriophage solutions as a sustainable alternative to traditional antibiotics. The company operates a research platform that creates customizable drugs aimed at replacing antibiotics in animal farming. By harnessing bacteriophages, which are natural predators of bacteria, Phagos seeks to provide an effective means to combat incurable and deadly infectious diseases. This innovative approach aligns with the growing need for alternatives to antibiotics in both human and veterinary medicine, addressing health challenges while promoting sustainable practices in agriculture.

Priothera Ltd is a clinical-stage company based in Dublin, Ireland, with an additional location in Saint Louis, France. It specializes in the development of orally applied sphingosine 1 phosphate (S1P) receptor modulators aimed at treating haematological malignancies. The company's primary focus is on its lead product, mocravimod, which is designed to enhance the curative potential of allogeneic haematopoietic stem cell transplants. By reducing the egress of T cell subsets from lymphatic tissues, Priothera's modulators aim to provide dual inhibition of graft versus host disease while also promoting graft versus leukemia effects, ultimately improving patient outcomes in this challenging area of medicine.

Vaxxel is a biotechnology company focused on developing innovative live-attenuated vaccines targeting critical respiratory diseases, specifically bronchiolitis and pneumonia caused by pneumoviruses. The company specializes in creating novel vaccine candidates aimed at treating infections associated with human metapneumovirus and the human respiratory virus. By leveraging its proprietary platform, Vaxxel aims to provide effective solutions for healthcare providers to combat these significant health challenges.

Brenus Pharma is focused on developing cell-based immunotherapies aimed at treating solid tumors. The company utilizes an allogeneic platform to create anti-cancer cell vaccines, which leverage the patient's immune system to combat cancer and reduce the risk of treatment resistance. Their approach emphasizes generating multiple candidate therapies efficiently, allowing for cost-effective scaling and integration with existing treatment standards. With a strong intellectual property portfolio and a team of experienced professionals, including renowned oncologists, Brenus Pharma seeks to educate the immune system to recognize and respond to tumor-associated and tumor-specific antigens, enhancing the effectiveness of chemotherapy and radiotherapy in cancer care.

SeaBeLife Biotech SAS is a biotechnology company based in Roscoff, France, established in 2019. The company focuses on developing innovative drug candidates aimed at treating acute pathologies, particularly acute liver and renal failure. SeaBeLife's products are derived from a family of patented molecules designed to block regulated necrosis, a type of regulated cell death. By targeting two synergistic pathways involved in various acute and chronic diseases, SeaBeLife aims to establish a new standard of care for patients with significant unmet medical needs. Through its research and development efforts, the company seeks to enhance patient outcomes and reduce complications associated with serious health conditions.

CarbonWorks specializes in the development of algae photobioreactors that utilize microalgae to capture and convert carbon dioxide. The company's technology industrializes microalgal photosynthesis, enabling the transformation of carbon emissions from various manufacturers into biomass. This biomass can be used in agricultural biocontrol products, as well as in human and animal food markets. By focusing on the large-scale production of safe bioproducts, CarbonWorks aims to help industries reduce their carbon footprints and promote sustainability.

Cell-Easy SAS is a contract development and manufacturing organization based in Toulouse, France, specializing in stem cell services for preclinical and clinical drug development. Founded in 2017, the company focuses on providing ready-to-inject adipose-derived allogeneic stem cells, utilizing biological material from healthy donors. This approach enables the healthcare industry to reduce manufacturing costs associated with stem cell therapies, addressing affordability challenges in the field. By streamlining access to these stem cells, Cell-Easy supports various development projects aimed at improving patient outcomes.

Elicit Plant is an agro-biotech company focused on enhancing the resilience of crops to water stress and developing phytosterol-based solutions. By leveraging proprietary technology, Elicit Plant aims to address the challenges posed by climate change on agriculture. The company’s products are designed to improve plant stress resistance and activate natural defenses, which has been validated through extensive field trials across three continents. These trials demonstrate that Elicit Plant's biosolutions provide farmers with consistent and significant returns on investment, positioning the company as a leader in the ecological transition within the agricultural sector.

Cureety is a telemedicine startup focused on enhancing the follow-up and care of cancer patients through its healthcare telemonitoring platform. The platform provides tools that support healthcare professionals in adjusting cancer treatments and collecting real-world data. This data collection not only aids in better patient care but also contributes to research initiatives, allowing researchers and industry stakeholders to advance their understanding and treatment of cancer. By transforming the care pathway for cancer patients, Cureety aims to improve overall patient outcomes and foster ongoing research programs in the field.